Engagement and Education Across the Cushing’s Disease Market During Q3 2025

All companies in the Cushing’s disease market maintained a digital presence across social media and corporate websites in Q3 2025. Three out of five operated branded sites, while two maintained unbranded pages.

Corcept Therapeutics raised awareness of excess cortisol and its effects through educational ad campaigns on the Korlym and Cushing’s Connection pages.

Crinetics Pharmaceuticals highlighted clinical updates, company culture, and key milestones, including a Nasdaq Bell event and a new look for a website.

Recordati Rare Diseases promoted its upcoming symposium focused on advancing Cushing’s syndrome management beyond hormone control.

Xeris Pharmaceuticals shared clinical data, welcomed new interns, and announced investor events, emphasizing innovation and patient care.